New Approved First-line Combining Therapy of NSCLC in 2020

In the past decades, lung cancer is considered one of lethal cancers all across world due to its evidenced greatest mortality and morbidity. Currently, main clinical treatment methods for involve surgery, chemotherapy, radiotherapy, anti-angiogenesis inhibitors tyrosine kinase inhibitors. field anticancer drugs, a variety new drugs have been emerging in recent years. They include chemotherapy with delivery modes, targeted inhibitors, angiogenesis immunotherapy that remained hot. But because cells complex escape mechanisms, effectiveness these single-drug treatments has disappointing. this case, number combination therapies emerged achieved relatively good results. According 2020 third edition NCCN guidelines, four multi-therapy regiments (Erlotinib plus ramucirumab, Erlotinib bevacizumab, Carboplatin albumin-bound paclitaxel atezolizumab Nivolumab ipilimumab) passed trials, adding first-line treatments. review, research provided an overview approved combining strategies addition predicting future drug development directions.